âMS is a chronic inflammatory disorder of the CNS caused by autoimmune reactivity of T cells towards CNS myelin components. MS progression inevitably leads to the loss of motor function, sensitive disturbances and cognitive impairment because of the immune mediated demyelination and axon degeneration. MS is one of the most common neurological disorders, which mainly affects young adults, and causes gradual decrease of their quality of life. Ten years after onset about 50% of patients have a chronic progressive course with this proportion increasing to 70 % after 15 years from disease onset and to 85 % after 25 years.
Conventional disease-modifying treatments do not provide satisfactory control of MS due to their inability to eradicate self-specific T cell clones. Immunosuppressive treatments, which are frequently used as second-line therapy, have also only partial beneficial effects. Recently, high-dose immunosuppressive therapy (HDIT) with AHSCT was proposed as a new and promising therapy for MS patientsâ Novik AA et al., Non-myeloablative Autologous Haematopoietic Stem Cell Transplantation with Consolidation Therapy using Mitoxantrone as a Treatment Option in Multiple Sclerosis Patients.
Journal of multiple sclerosis is a subscription free quarterly magazine dealing with the recent developments I n the field of multiple sclerosis research and treatment. The journal also considers the clinical issues related to multiple sclerosis with same priority. This newly started journal is a different approach towards this upcoming field of neurology research.
Last date updated on September, 2020